None
Quote | Morphic Holding Inc. (NYSE:MORF)
Last: | $ |
---|---|
Change Percent: | -11.12% |
Open: | $17.83 |
Close: | $17.50 |
High: | $18.485 |
Low: | $16.35 |
Volume: | 387,973 |
Last Trade Date Time: | 02/12/2020 04:42:28 pm |
News | Morphic Holding Inc. (NYSE:MORF)
2024-04-25 07:51:21 ET More on Morphic Seeking Alpha’s Quant Rating on Morphic Historical earnings data for Morphic Financial information for Morphic Read the full article on Seeking Alpha For further details see: Morphic GAAP EPS of -$0.91
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disea...
Message Board Posts | Morphic Holding Inc. (NYSE:MORF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Morphic Holding Inc. Company Name:
MORF Stock Symbol:
NYSE Market:
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disea...
Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.14 for Q1 2024 Agree Realty Corporation (ADC) is expected to report $1.01 for Q1 2024 1st Colonial Bancorp Inc (FCOB) is expected to report for Q1 2024 Equity Residential of Beneficial Interest (EQR) is expected to report $...
2024-04-13 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...